Your session is about to expire
← Back to Search
Group 2 (tamoxifen, omega-3 fatty acids) for Breast Cancer
Study Summary
This trial is testing whether taking tamoxifen, a drug that blocks the effects of estrogen, can reduce the risk of breast cancer in postmenopausal women who are overweight or obese and at higher
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Which individuals are eligible to participate in this research study?
"To be eligible for enrollment in this clinical trial, potential participants must have a diagnosis of breast cancer and fall within the age range of 45 to 65. A total of 66 candidates will be accepted into the study."
Has the Food and Drug Administration officially authorized Group 1 (tamoxifen) for medical usage?
"Given that this trial is in Phase 2, our team at Power rates the safety of Group 1 (tamoxifen) as a 2. Although there is some existing data supporting its safety, no efficacy data has been obtained yet."
Are there any ongoing efforts to enroll participants in this current medical study?
"Based on the information available on clinicaltrials.gov, it appears that this particular trial is not currently seeking participants. The initial posting of the study was recorded on June 16th, 2024, and the most recent update occurred on January 4th, 2024. However, there are a substantial number of other studies (specifically 4715) actively enrolling patients at this time."
Does the inclusion criteria of this medical study allow for participation by individuals aged 75 and above?
"Only individuals between the ages of 45 and 65 are eligible to participate in this clinical trial. It is worth noting that there are a total of 157 trials available for patients under the age of 18, while there are 4574 trials specifically targeting patients over the age of 65."
Share this study with friends
Copy Link
Messenger